Arginase I (human) (rec.) (highly active)
| Code | Size | Price |
|---|
| AG-40T-0124-C010 | 10 ug | £227.00 |
Quantity:
| AG-40T-0124-3010 | 3 x 10 ug | £537.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: E.coli
Regulatory Status: RUO
Target Species: Human
Shipping:
Dry Ice
Storage:
-80°C
Documents
Further Information
Alternate Names/Synonyms:
EC 3.5.3.1; ARG1; Arginase 1; Type I Arginase; Liver-type Arginase; L-Arginase
Biological Activity:
1.6 ?0.2U/µg protein. One unit is defined as the amount of enzyme that converts 1µmol of L-arginine to L-ornithine and urea per min. at 37°C, pH 9.5 (according to protocol from R.T. Schimke, et al.; J. Biol. Chem. 238, 1012 (1963)).
Concentration:
0.2µg/µl
EClass:
32160000
Form (Short):
liquid
Formulation:
Liquid. In 10mM TRIS-HCl, pH 7.5, containing 1mM beta-mercaptoethanol, 1mM MnCl2 and 50% glycerol.
Handling Advice:
Avoid freeze/thaw cycles.
Long Description:
Protein. Full length human arginase I. Source: E. coli. Liquid. In 10mM TRIS-HCl, pH 7.5, containing 1mM beta-mercaptoethanol, 1mM MnCl2 and 50% glycerol. Purity: >90% (SDS-PAGE). Arginase catalyzes the hydrolysis of arginine to ornithine and urea. At least two isoforms of mammalian arginase exist (types I and II) which differ in their tissue distribution, subcellular localization, immunologic crossreactivity and physiologic function. The type I isoform is a cytosolic enzyme and expressed predominantly in the liver as a component of the urea cycle. Inherited deficiency of this enzyme results in argininemia, an autosomal recessive disorder characterized by hyperammonemia. Arginase is involved in the nitric oxide (NO) pathway and immune cell arginine metabolism. It is fundamentally involved in cancer, inflammation, infections, fibrotic diseases, neurobiology, pregnancy and immune regulation in general.
Molecular Weight:
34.7kDa
NCBI, Uniprot Number:
P05089
Package Type:
Plastic Vial
Product Description:
Arginase catalyzes the hydrolysis of arginine to ornithine and urea. At least two isoforms of mammalian arginase exist (types I and II) which differ in their tissue distribution, subcellular localization, immunologic crossreactivity and physiologic function. The type I isoform is a cytosolic enzyme and expressed predominantly in the liver as a component of the urea cycle. Inherited deficiency of this enzyme results in argininemia, an autosomal recessive disorder characterized by hyperammonemia. Arginase is involved in the nitric oxide (NO) pathway and immune cell arginine metabolism. It is fundamentally involved in cancer, inflammation, infections, fibrotic diseases, neurobiology, pregnancy and immune regulation in general.
Purity:
>90% (SDS-PAGE)
Sequence:
Full length human arginase I.
Source / Host:
E. coli
Transportation:
Non-hazardous
UNSPSC Category:
Other Proteins
UNSPSC Number:
12352202
Use & Stability:
Stable for at least 1 year after receipt when stored at -80°C.
References
Determination of arginase activity in macrophages: a micromethod: I.M. Corraliza, et al.; J. Immunol. Methods 174, 231 (1994) | Th1/Th2-regulated expression of arginase isoforms in murine macrophages and dendritic cells: M. Munder, et al.; J. Immunol. 163, 3771 (1999) | Implications of the S-shaped domain in the quaternary structure of human arginase: A. Mora, et al.; Biochim. Biophys. Acta 1476, 181 (2000) | Glu-256 is a main structural determinant for oligomerisation of human arginase I: G. Sabio, et al.; FEBS Letters 501, 161 (2001) | Crystal structure of human arginase I at 1.29-? resolution and exploration of inhibition in the immune response: L. Di Costanzo, et al.; PNAS 102, 13058 (2005)
Related Products
| Product Name | Product Code | Supplier | Sauchinone | AG-CN2-0032 | AdipoGen Life Sciences | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|